Abstract
AbstractChronic distress-induced hypothalamic-pituitary-adrenal axis deregulations have been associated with the development of neuropsychiatric disorders such as anxiety and depression. Currently available drugs treating such pathological conditions have limited efficacy and diverse side effects, revealing the need of new safer strategies. Aromatic plant-based compounds are largely used in herbal medicine due to their therapeutic properties on mood, physiology, and general well-being. The purpose of this study was to investigate the effects of 2-phenylethyl alcohol (PEA), one of the pharmacologically active constituents of rose essential oil, on chronic corticosterone (CORT)-induced behavioral and neurobiological changes in female mice. Animals followed a prolonged PEA inhalation exposure (30 min per day) for 15 consecutive days prior to behavioral evaluation with open-field, forced swim and novelty-suppressed feeding tests. CORT treatment induced an anxio-depressive-like phenotype, evidenced by a reduced locomotor activity in the open-field, and an increased latency to feed in the novelty-suppressed feeding paradigms. To elucidate the neural correlates of our behavioral results, cerebral cFos expression analysis was further performed to provide a global map of neuronal activity. The altered feeding behavior was accompanied by a significant decrease in the number of cFos-positive cells in the olfactory bulb, and altered brain connectivity as shown by cross-correlation-based network analysis. CORT-induced behavioral and neurobiological alterations were reversed by prolonged PEA inhalation, suggesting a therapeutic action that allows regulating the activity of neural circuits involved in sensory, emotional and feeding behaviors. These findings might contribute to better understand the therapeutic potential of PEA on anxio-depressive symptoms.
Publisher
Cold Spring Harbor Laboratory
Reference100 articles.
1. American Psychiatric Association, American Psychiatric Association, eds., Diagnostic and statistical manual of mental disorders: DSM-5, 5th ed, American Psychiatric Association, Washington, D.C, 2013.
2. R.M. Hirschfeld , M. Weissman , Risk factors for major depression and bipolar disorder, Neuropsychopharmacol. Fifth Gener. Prog. (2002) 1017–1025.
3. Prevalence of depression in the community from 30 countries between 1994 and 2014, Sci;Rep,2018
4. The importance of anxiety in both major depression and bipolar disorder: importance of anxiety in MDD and GAD., Depress;Anxiety,2012
5. Comorbidity of depressive and anxiety disorders;challenges in diagnosis and assessment,2014